Protara Therapeutics
New York
About Protara Therapeutics
Protara Therapeutics develops transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy created for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. The Protara team prioritizes creativity, diverse perspectives, and tenacity to expedite their goal of bringing life-changing therapies to people with limited treatment options.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $224.2M
- Funding stage: M&A
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:TARA
- Website: protaratx.com
- Phone: 646-844-0337
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/protara-therapeutics-37632 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.